BRAF and metastatic melanoma: Following the results of pivotal Phase I CheckMate-069 (NCT01927419) and Phase III Checkmate-067 study (NCT01844505) testing the efficacy of nivolumab vs. nivolumab + ipilimumab [37,38], the combination of these two agents have been approved for the treatment of unresectable or metastatic melanoma, firstly in BRAF unmutated cases in Oct 2015, which has been further expanded independently on the BRAF mutation status in Jan 2016.